These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 705407)

  • 1. Circulating anticoagulant associated with chronic active hepatitis.
    Zinn WM; Graham DY; Grose NP; Frankel N
    South Med J; 1978 Oct; 71(10):1308-9. PubMed ID: 705407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor XI and factor XII as targets for new anticoagulants.
    Weitz JI
    Thromb Res; 2016 May; 141 Suppl 2():S40-5. PubMed ID: 27207423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Salicylic acid derivatives used as anticoagulants].
    Bruhn HD
    Verh Dtsch Ges Inn Med; 1971; 77():1035-7. PubMed ID: 5155959
    [No Abstract]   [Full Text] [Related]  

  • 4. Factors IX, XI, and XII: potential therapeutic targets for anticoagulant therapy in atherothrombosis.
    Rai V; Balters MW; Agrawal DK
    Rev Cardiovasc Med; 2019 Dec; 20(4):245-253. PubMed ID: 31912715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid loss of factor XII and XI activity in ellagic acid-activated normal plasma: role of plasma inhibitors and implications for automated activated partial thromboplastin time recording.
    Joist JH; Cowan JF; Khan M
    J Lab Clin Med; 1977 Dec; 90(6):1054-65. PubMed ID: 303667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proceedings: Inhibition of blood coagulation factor XI-XII by monoclonal IgM.
    Valentin IR; Rimon A; Lahav M
    Isr J Med Sci; 1975 Dec; 11(12):1392. PubMed ID: 815201
    [No Abstract]   [Full Text] [Related]  

  • 7. Anticoagulant activities of heparin and fragments.
    Barrowcliffe TW; Thomas DP
    Ann N Y Acad Sci; 1989; 556():132-45. PubMed ID: 2660683
    [No Abstract]   [Full Text] [Related]  

  • 8. [Report of two cases of circulating anticoagulant directed against factor xi (author's transl)].
    Vila M; Monasterio J; Arangüena PV; Valentin P; Pico M; Triginer J
    Sangre (Barc); 1978; 23(2):202-9. PubMed ID: 653555
    [No Abstract]   [Full Text] [Related]  

  • 9. Recurrent thrombosis in a young woman with a circulating anticoagulant directed against factors XI and XII.
    Aberg H; Nilsson IM
    Acta Med Scand; 1972 Nov; 192(5):419-25. PubMed ID: 5083382
    [No Abstract]   [Full Text] [Related]  

  • 10. The anticoagulant activity of lysosomal cationic proteins from polymorphonuclear leukocytes.
    Saba HI; Roberts HR; Herion JC
    J Clin Invest; 1967 Apr; 46(4):580-9. PubMed ID: 6021205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [BLOOD CLOTTING FACTOR IN HEMOLYSATES].
    OGIWARA Y
    Nihon Ketsueki Gakkai Zasshi; 1963 Dec; 26():779-87. PubMed ID: 14154695
    [No Abstract]   [Full Text] [Related]  

  • 12. Minimal-change glomerulonephritis associated with circulating anticoagulant to factor XII.
    Bateman D; Gokal R; Prescott R; Hamilton PJ; Kerr DN
    Br Med J; 1980 Aug; 281(6236):358. PubMed ID: 7427279
    [No Abstract]   [Full Text] [Related]  

  • 13. [Reactions initiating blood coagulation].
    Zubairov DM; Baĭkeev RF
    Ukr Biokhim Zh (1978); 1983; 55(3):281-4. PubMed ID: 6553424
    [No Abstract]   [Full Text] [Related]  

  • 14. Procainamide-induced circulating anticoagulants in a congenitally-deficient factor XI patient.
    Clyne LP; Farber LR; Chopyk RL
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(2):239-44. PubMed ID: 2475403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the product of the reaction between activated Hageman factor (factor XII) and plasma thromboplastin antecedent (factor XI).
    Ratnoff OD
    J Lab Clin Med; 1972 Nov; 80(5):704-10. PubMed ID: 4673237
    [No Abstract]   [Full Text] [Related]  

  • 16. THROMBOPLASTIC ENZYMES.
    FERGUSON JH; ENNIS EG; IATRIDIS PG
    Fed Proc; 1964; 23():762-72. PubMed ID: 14195460
    [No Abstract]   [Full Text] [Related]  

  • 17. A case of IgM antibodies which inhibit the contact activation of blood coagulation.
    Criel A; Collen D; Masson PL
    Thromb Res; 1978 May; 12(5):883-92. PubMed ID: 566967
    [No Abstract]   [Full Text] [Related]  

  • 18. The lupus inhibitor: a study of its heterogeneity.
    Coots MC; Miller MA; Glueck HI
    Thromb Haemost; 1981 Dec; 46(4):734-9. PubMed ID: 7330826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator.
    Forbes CD; Pensky J; Ratnoff OD
    J Lab Clin Med; 1970 Nov; 76(5):809-15. PubMed ID: 5477337
    [No Abstract]   [Full Text] [Related]  

  • 20. [ON THE ORIGIN OF THE ERYTHROCYTIC THROMBOPLASTIC FACTOR].
    KUZNIK BI; NAUMOV AD
    Vopr Med Khim; 1964; 10():140-4. PubMed ID: 14231597
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.